2015 American Transplant Congress
Comparison of T Regulatory (Treg) Cell Function Pre- and Post-Lung Transplantation Shows a Major Negative Impact of Immunosuppression on Treg Function
Aim: Clinical lung Tx recipients do not have sustained long-term survival outcomes comparable to that of other recipients of solid organ allografts, despite generally comparable…2015 American Transplant Congress
Stable and Unstable Chimerism During Immunosuppressive Drug Withdrawal in Tolerant Recipients of HLA Matched Combined Kidney and Hematopoietic Cell Transplants
1Surgery, Stanford University, Palo Alto, CA; 2Medicine, Stanford University, Palo Alto, CA.
Our previous studies showed that 75-80% of HLA matched recipients of combined kidney and hematopoietic cell transplants conditioned with total lymphoid irradiation (TLI) and anti-thymocyte…2015 American Transplant Congress
Everolimus and Early Calcineurin Inhibitor Withdrawal Is Associated With Superior Renal Function: 5-Year Follow-Up of the Randomized PROTECT Liver Transplantation Study
PROTECT Study Group, Novartis Pharma GmbH, Germany.
Purpose: At the end of the 12-month (M) PROTECT core study (NCT00378014), de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)…2015 American Transplant Congress
Proximal Tubular Dysfunction Is Common After the First Year of Kidney Transplantation
Background: After the initial period of kidney transplantation, the prevalence of proximal tubular dysfunction (PTD) and its consequences are unknown. The aim of this study…2015 American Transplant Congress
Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus
AIM:Immunosuppression with an mTOR inhibitor plus calcineurin inhibitor (CNI) minimization is increasingly used in liver transplantation to protect against the nephrotoxic and neurotoxic side effects…2015 American Transplant Congress
Current Status of US Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Intestine Transplant Registry
The purpose of this study is to analyze the current status of US intestinal transplantation (IT). As of 9/19/2014, 2441 IT have been performed in…2015 American Transplant Congress
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype
1University Medicine Charité, Berlin, Germany; 2Labor Berlin GmbH, Berlin, Germany.
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result…2015 American Transplant Congress
Immune Phenotyping of Peripheral Blood Samples from the CTOT-10 Belatacept Study
The purpose of the CTOT-10 study is to evaluate belatacept as maintenance therapy, while minimizing calcineurin inhibitors and corticosteroids in renal transplantation. We designed mechanistic…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Pyridoxine Deficiency After Solid Organ Transplant
BackgroundMicronutrient deficiencies have been discussed in the literature regarding post-transplant recipients. A proposed theory is that immunosuppressive medications or altered immune system cause pyridoxine deficiency…
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 138
- Next Page »